Recurrent Clostridioides difficile infection (rCDI) is a significant clinical challenge, defined as recurrence of symptoms within 8 weeks of completing treatment for a previous episode.
rCDI occurs in approximately 15-30% of patients after initial CDI.
Recurrence occurs in roughly 20–25% after a first episode and 40–45% after a second, with a smaller subset developing multiple recurrences.
Risk increases with each recurrence (up to 60% after second episode)
Patient risk factors:
Advanced age (>65 years) Immunosuppression Inflammatory bowel disease Chronic kidney disease Previous CDI episodes Continued antibiotic exposure that disrupts gut microbiome Proton pump inhibitor use Inadequate initial treatment Microbiologic reasons-Ribotype 027 and other hypervirulent strains Impaired immune response to toxins Disrupted gut microbiota
Recurrent CDI is defined as recurrence of diarrhea within eight weeks of symptom resolution and completion of treatment for previous CDI episode.
rCI differs clinically from refractory CDI, which is rare and involves lack of response to initial treatment, usually occurring with fulminant infection.
CDI can recur because despite treatment spores can persist in the colon and may germinate and produce toxins if the microbiota is further disrupted.
In up to 50% of rCI caused by ingestion of spores from a new toxin producing strain.
Diagnostic tests for CDI include toxin enzyme immunoassays, which detect free toxins, nucleic acid amplification tests which detect CD toxin genes and glutamate dehydrogenase enzyme produced by all CD strains, even those that do not produce toxins.
The management strategy escalates with each recurrence:
First recurrence
Vancomycin (tapered/pulsed regimen) OR Fidaxomicin (preferred due to lower recurrence rates)
Second or subsequent recurrences:
Fecal microbiota transplantation (FMT)- highly effective (80-90% cure rate) Fidaxomicin Vancomycin followed by rifaximin Bezlotoxumab (monoclonal antibody against toxin B) – can be added to standard antibiotics
Prevention Strategies
Judicious antibiotic use
Consider bezlotoxumab for high-risk patients Probiotic evidence remains controversial
FMT has become the standard of care for multiple recurrences Each recurrence increases risk of subsequent episodes Breaking the cycle requires restoring healthy gut microbiota Secondary prevention is critical in high-risk patients
Recurrent difficile infection (rCDI) is common and increasingly preventable with optimized antibiotics, adjunctive bezlotoxumab, and microbiota-based therapies such as FMT or live biotherapeutics.
Fidaxomicin (FDX):mNarrow‑spectrum, spares more commensals, and improves sustained response versus vancomycin in recurrent CDI, especially with extended‑pulsed regimens.
Oral vancomycin taper/pulse:-Common, guideline‑endorsed strategy; examples include gradual dose reduction then spaced dosing over several weeks, though specific schedules vary by institution.
Bezlotoxumab (BEZ): Single IV anti–toxin B monoclonal; RCTs and real‑world data show ~50% relative reduction in rCDI at 12 weeks and fewer 90‑day readmissions vs SOC alone.
Avoid unnecessary systemic antibiotics and minimize high‑risk agents where alternatives exist; reassess each new antimicrobial course.
Review need for chronic proton pump inhibitor therapy and deprescribe when possible, particularly in patients with prior CDI.
Emphasize infection‑control measures (contact precautions, handwashing with soap and water, environmental sporicidal cleaning) to prevent reinfection and transmission.
Confirming that recurrence is true CDI diarrhea plus positive test rather than post‑infectious IBS or alternate colitis.